Cambrex Corp. (CBM) Downgraded to Hold at Zacks Investment Research
According to Zacks, “Cambrex Corporation manufactures and markets a broad line of specialty chemicals and commodity chemical intermediates and also manufactures chemicals to customer specifications. There are five product categories: pharmaceutical bulk actives; pharmaceutical intermediates; organic intermediates; performance enhancers; and polymer systems. “
Cambrex Corp. (NYSE:CBM) opened at 45.22 on Tuesday. Cambrex Corp. has a one year low of $29.50 and a one year high of $59.41. The company has a market cap of $1.45 billion, a PE ratio of 22.86 and a beta of 1.45. The firm’s 50-day moving average price is $45.28 and its 200-day moving average price is $47.69.
Cambrex Corp. (NYSE:CBM) last released its earnings results on Thursday, July 28th. The company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.09. Cambrex Corp. had a return on equity of 24.86% and a net margin of 13.97%. The firm earned $118.22 million during the quarter, compared to the consensus estimate of $114.85 million. During the same period in the prior year, the company posted $0.63 EPS. The company’s revenue was up 10.9% compared to the same quarter last year. On average, equities research analysts forecast that Cambrex Corp. will post $2.56 earnings per share for the current fiscal year.
In other news, Director William B. Korb sold 3,420 shares of the business’s stock in a transaction on Monday, July 11th. The stock was sold at an average price of $55.00, for a total transaction of $188,100.00. Following the completion of the transaction, the director now owns 23,982 shares of the company’s stock, valued at approximately $1,319,010. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 2.63% of the company’s stock.
A number of institutional investors have recently modified their holdings of CBM. Tower Research Capital LLC TRC purchased a new position in shares of Cambrex Corp. during the second quarter worth about $106,000. Acrospire Investment Management LLC boosted its position in shares of Cambrex Corp. by 149.0% in the second quarter. Acrospire Investment Management LLC now owns 2,674 shares of the company’s stock worth $138,000 after buying an additional 1,600 shares during the last quarter. BlackRock Inc. boosted its position in shares of Cambrex Corp. by 38.6% in the second quarter. BlackRock Inc. now owns 2,855 shares of the company’s stock worth $149,000 after buying an additional 795 shares during the last quarter. Intrust Bank NA purchased a new position in shares of Cambrex Corp. during the second quarter worth about $206,000. Finally, PineBridge Investments L.P. boosted its position in shares of Cambrex Corp. by 4.4% in the second quarter. PineBridge Investments L.P. now owns 4,056 shares of the company’s stock worth $210,000 after buying an additional 171 shares during the last quarter. 99.46% of the stock is owned by institutional investors and hedge funds.
About Cambrex Corp.
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Receive News & Stock Ratings for Cambrex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corp. and related stocks with our FREE daily email newsletter.